Response-Guided therapy for chronic hepatitis C virus infection in patients coinfected with HIV: A pilot trial

Clinical Infectious Diseases

Volumn 48, Issue 8, 2009, Pages 1152-1159

  Van Eynde, Eva Den ^a   Crespo, Manuel ^a,d   Esteban, Juan I ^b   Jardi, Rosend ^c   Ribera, Esteban ^a   Carbonell, Judit ^b   Rodriguez Frias, Francisco ^c   Vicenc ^a   Adria ^a   Imaz, Arkaitz ^a   Saz, Sara Villar Del ^a   Ocaña, Inma ^a   Esteban, Rafael ^b   Pahissa, Albert ^a  

^a Infectious Diseases Department   (Spain)

^b Liver Unit   (Spain)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ERYTHROPOIETIN; PEGINTERFERON ALPHA2B; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ANEMIA; ARTICLE; BLOOD TOXICITY; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; FEASIBILITY STUDY; FEMALE; FLU LIKE SYNDROME; GENOTYPE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; MUCOSA INFLAMMATION; NEUROTOXICITY; PNEUMONIA; PRIORITY JOURNAL; RECURRENCE RISK; TERTIARY HEALTH CARE; TREATMENT DURATION; TREATMENT RESPONSE; VIRUS LOAD;

ADULT; ANALYSIS OF VARIANCE; ANTIVIRAL AGENTS; CHI-SQUARE DISTRIBUTION; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HIV INFECTIONS; HOSPITALS; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; PILOT PROJECTS; POLYETHYLENE GLYCOLS; RIBAVIRIN; RNA, VIRAL; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; VIRAL LOAD;

EID: 63649149923     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/597470     Document Type: Article

References (39)

1. NIH Consensus Development Conference Statement: management of hepatitis C. Gastroenterology 2002; 123:2082-99.
2. Dienstag JL, McHutchison JG. American Gastroenterological Association medical position statement on the management of hepatitis C. Gastroenterology 2006; 130:225-30.
3. Alberti A, Clumeck N, Gerlich W, Lundgren J, Palù G, Reiss P. Short statement of the first European Consensus Conference on the treatment of chronic hepatitis B and C in HIV coinfected patients. Journal of Hepatology 2005;42:615-24.
4. Soriano V, Puoti M, Sulkowski M, et al. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 2007;21:1073-89.
5. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003; 38: 645-52.
6. Torriani EI, Rodriguez-Torres M, Rockstroh IK, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV- infected patients. N Engl J Med 2004;351:438-50.
7. Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006;43:954-60.
8. Dalgard O, Bjoro K, Helium KB, et al. Treatment with pegylated interferon and ribavirin in HCV infection with genotype 2 or 3 for 14 weeks: a pilot study. Hepatology 2004;40:1260-5.
9. von Wagner M, Huber M, Berg T, et al. Peginterferon alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. Gastroenterology 2005; 129:522-7.
10. Mangia A, Santoro R, Minerva N, et al. Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. N Engl J Med 2005;352:2609-17.
11. Shiftman ML, Suter F, Bacon BR, et al. Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV genotype 2 or 3. N Engl J Med 2007;357:124-34.
12. Zeuzem S, Buti M, Ferenci P, et al. Efficacy of 24 weeks treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C infected with genotype 1 and low pretreatment viremia. f Hepatol 2006;44:97-103.
13. Ferenci P, Laferl H, Scherzer TM, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008; 135:451-8.
14. Berg T, von Wagner M, Nasser S, et al. Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon alfa-2a plus ribavirin. Gastroenterology 2006;130:1086-97.
15. Mangia A, Minerva N, Bacca D, et al. Individualized treatment duration for hepatitis C genotype 1 patients: a randomized controlled trial. Hepatology 2008;47:43-50.
16. Pearlman BL, Ehleben C, Saifee S. Treatment extension to 72 weeks of peginterferon and ribavirin in hepatitis C genotype 1-infected slow responders. Hepatology 2007;46:1688-94.
17. Ballesteros AL, Franco S, Fuster D, et al. Early HCV dynamics on peginterferon and ribavirin in HIV/HCV coinfection: indications for the investigation of new treatment approaches. AIDS 2004;18:59-66.
18. Nunez M, Marino A, Miralles C, et al. Baseline serum hepatitis C virus (HCV) RNA level and response at week 4 are the best predictors of relapse after treatment with pegylated interferon plus ribavirin in HIV/ HCV-coinfected patients. J Acquir Immune Dene Syndr 2007;45: 439-44.
19. Payan C, Pivert A, Morand P, et al. Rapid and early virological response to chronic hepatitis C treatment with IFN alpha2b or PEG-IFN alpha- 2b plus ribavirin in HIV/HCV-coinfected patients. Gut 2007; 56: 1111-6.
20. Kang M, Chung RT. The role of early viral decline in the treatment of hepatitis C in HIV-1-coinfected persons. J Acquir Immune Defic Syndr 2007;46:371-3.
21. Laguno M, Larrousse M, Murillas J, et al. Predictive value of early virologic response in HIV/hepatitis C virus-coinfected patients treated with an interferon-based regimen plus ribavirin. I Acquir Immune Defic Syndr 2007;44:174-8.
22. Crespo M, Sauleda S, Esteban JI, et al. Peginterferon alpha-2b plus ribavirin vs interferon alpha-2b plus ribavirin for chronic hepatitis C in HIV-coinfected patients. J Viral Hepat 2007;14:228-38.
23. Crespo M, Esteban JI, Ribera E, et al. Utility of week-4 viral response to tailor treatment duration in hepatitis C virus genotype 3/ HIV-coinfected patients. AIDS 2007;21:477-81.
24. Laguno M, Murillas J, Blanco JL, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for treatment of HIV/HCV-oinfected patients. AIDS 2004; 18:F27-36.
25. Carrat F, Bani-Sadr F, Pol S, et al. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial. JAMA 2004; 292: 2839-48.
26. Chung RT, Andersen J, Volberding P, et al. Peginterferon alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med 2004;351:451-9.
27. Esteban JI, Esteban R, Viladomiu L, et al. Hepatitis C virus antibodies among risk groups in Spain. Lancet 1989;2:294-7.
28. Hopkins S, Lambourne J, Farrell G, et al. Role of individualization of hepatitis C virus (HCV) therapy duration in HIV/HCV-coinfected individuals 2. HIV Med 2006;7:248-54.
29. Kamal SM, El Kamary SS, Shardell MD, et al. Pegylated interferon alpha-2b plus ribavirin in patients with genotype 4 chronic hepatitis C: the role of rapid and early virologic response. Hepatology 2007; 46: 1732-40.
30. Drusano GL, Preston SL. A 48-week duration of therapy with pegylated interferon alpha 2b plus ribavirin may be too short to maximize long- term response among patients infected with genotype 1 hepatitis C virus. J Infect Dis 2004;189:964-70.
31. Fuster D, Planas R, Gonzalez J, et al. Results of a study of prolonging treatment with pegylated interferon alpha-2a plus ribavirin in HIV/ HCV-coinfected patients with no early virological response. Antivir Ther 2006;11:473-82.
32. Nunez M, Miralles C, Berdun MA, et al. Role of weight-based ribavirin dosing and extended duration of therapy in chronic hepatitis C in HIV-infected patients: the PRESCO trial. AIDS Res Hum Retroviruses 2007;23:972-82.
33. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon alpha-2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004; 140:346-55.
34. Shiffman ML, Salvatore J, Hubbard S, et al. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology 2007;46:371-9.
35. Dixit NM, Layden-Almer JE, Layden TJ, Perelson AS. Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 2004;432:922-4.
36. Jacobson IM, Brown RS Jr, Freilich B, et al. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. Hepatology 2007;46:971-81.
37. Bani-Sadr F, Carrat F, Pol S, et al. Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy. J Acquir Immune Defic Syndr 2005;40:47-52.
38. Bani-Sadr F, Carrat F, Rosenthal E, et al. Spontaneous hepatic decompensation in patients coinfected with HIV and hepatitis C virus during interferon-ribavirin combination treatment. Clin Infect Dis 2005;41: 1806-9.
39. Mauss S, Valenti W, DePamphilis J, et al. Risk factors for hepatic decompensation in patients with HIV/HCV coinfection and liver cirrhosis during interferon-based therapy. AIDS 2004; 18:F21-5.